Welcome to our dedicated page for Intest SEC filings (Ticker: INTT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The inTEST Corporation (INTT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. inTEST, a global supplier of test and process technology solutions for semiconductor, automotive/EV, defense/aerospace, industrial, life sciences, and safety/security markets, uses these filings to report financial results, corporate actions, and shareholder matters.
Recent Form 8-K filings show how inTEST reports material events such as the release of quarterly financial results and the outcomes of its annual meeting of stockholders. For example, the company has filed current reports to furnish press releases covering results for quarters ended June 30 and September 30, and to disclose voting results on director elections, auditor ratification, and advisory votes on executive compensation and the frequency of such votes.
In addition to current reports, investors typically look to inTEST’s annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed information on revenue by market and segment, gross margin, operating expenses, net income or loss, and non-GAAP measures such as adjusted net earnings and adjusted EBITDA. These periodic reports also explain how management uses orders and backlog as key performance indicators and provide narrative discussion of market conditions, diversification efforts, and cost management.
On Stock Titan, SEC documents for INTT are supplemented with AI-powered summaries that highlight the main points of lengthy filings, such as 10-K and 10-Q reports. The platform also surfaces real-time updates from EDGAR, helping users quickly identify new 8-Ks and other submissions. For those monitoring governance and compensation, proxy-related disclosures and shareholder vote results are available, while Form 4 and related insider transaction filings can be reviewed to see reported trading activity by directors and officers.
inTEST Corp President & CEO Richard N. Grant Jr. reported new equity awards and a small share sale. He received 13,822 restricted shares that vest in four equal annual installments starting on March 16, 2027, and 13,822 performance-based restricted shares that may vest in March 2029 depending on performance, with a maximum of 20,733 shares vesting at above-target results. He was also granted an option for 23,365 shares of common stock at an exercise price of $14.47, vesting over four years beginning on March 16, 2027.
On March 18, 2026, Grant sold 1,636 common shares at a weighted average price of $14.279 per share to satisfy tax withholding obligations tied to restricted stock vesting, under a Rule 10b5-1 trading plan adopted on December 8, 2023. After this sale, he directly owns 212,730 common shares. He also continues to hold multiple option grants with exercise prices ranging from $7.74 to $16.06 and expiration dates between 2031 and 2035.
Maginnis Gerald J. reported acquisition or exercise transactions in this Form 4 filing.
INTEST CORP director Gerald J. Maginnis received an award of 12,000 shares of Common Stock on March 16, 2026. The grant carried a price of $0.0000 per share, indicating a share-based award rather than a market purchase. After this transaction, he directly holds 96,057 shares.
DEWS JOSEPH W IV reported acquisition or exercise transactions in this Form 4 filing.
INTEST CORP director Joseph W. Dews IV received an equity award of 12,000 shares of Common Stock on March 16, 2026. The shares were granted at no cash cost per share as compensation, not bought on the open market. After this award, he directly holds 130,250 shares in total.
ABRAMS STEVEN J reported acquisition or exercise transactions in this Form 4 filing.
INTEST CORP director Steven J. Abrams received a grant of 12,000 shares of Common Stock on March 16, 2026, at no stated purchase price. After this award, he holds 21,000 shares directly. An additional 87,000 shares are held indirectly through the Steven J. Abrams Revocable Trust.
INTEST CORP director Jeffrey A. Beck received an award of 12,000 shares of common stock. The grant was recorded at no cash cost per share and represents a compensation-related acquisition rather than an open-market purchase. After this grant, Beck directly holds 79,500 shares of INTT common stock.
INTEST CORP reported a proposed sale of Common Stock on a Form 144. The filing lists a broker-dealer (Citigroup Global Markets, Inc.) and a Restricted Stock Aware Vesting entry showing 6,460 shares. It also discloses two recent sales by Grant Richard N. Jr: 1,097 shares on 03/09/2026 for $14,618.51 and 1,397 shares on 03/11/2026 for $19,786.97.
inTEST Corporation provides an overview of its business for the year ended December 31, 2025, highlighting a diversified test and process technology portfolio across semiconductor, Auto/EV, Defense/Aerospace, Industrial, Life Sciences and Safety/Security markets. About 68% of 2025 revenue, or $77.9 million, came from markets outside semiconductor, reflecting progress on its VISION 2030 diversification strategy.
The company completed the acquisition of Alfamation S.p.A. for a total purchase price of $21.9 million, expanding automotive and specialty consumer electronics test capabilities and adding a related-party facility lease in Italy. It also consolidated Videology’s Netherlands operations into Massachusetts, incurring $0.8 million in severance charges and expecting about $0.3 million of remaining lease costs.
Backlog grew to $53.9 million at December 31, 2025, up from $39.5 million a year earlier, and inTEST ended the year with 407 employees. The filing also describes segment structures, key products, competitive landscape, acquisition and growth risks, supply chain exposure, AI and cybersecurity risks, and details of its $3.8 million debt with M&T Bank and related covenant waivers.
INTEST CORP President & CEO Richard N. Grant Jr. reported open-market sales of company common stock that were used to cover taxes on vesting restricted stock. He sold 1,397 shares at $14.1639 per share and 1,097 shares at $13.3259 per share pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on December 8, 2023. After these transactions, he holds 186,722 common shares directly and maintains multiple employee stock option awards, including options expiring between 2031 and 2035 with exercise prices ranging from $7.7400 to $16.0600.
INTEST CORP Division President–Electronic Test, Joseph Richard McManus Jr., reported tax-related share withholdings rather than open-market trades. On March 6 and 8, 2026, a total of 333 shares of common stock were withheld at $13.24 per share to cover tax obligations on vesting restricted stock. After these transactions, he directly holds 30,919 shares of common stock. He also retains multiple employee stock options, including grants exercisable at $7.74, $8.14, $11.33, $13.13, and $16.06 per share with expirations between 2031 and 2035, several of which vest in equal annual installments.
INTEST CORP division president Richard B. Rogoff reported routine share dispositions to cover taxes on equity compensation. On March 6 and March 8, 2026, a total of 291 shares of common stock were withheld at $13.24 per share to satisfy tax withholding obligations on vesting restricted stock.
After these tax-withholding dispositions, Rogoff directly holds 6,787 shares of common stock. He also holds equity awards that may convert into additional shares, including 4,040 restricted stock units that vest in four equal annual installments starting on March 17, 2026, and several stock option grants covering underlying common shares at exercise prices between $7.74 and $16.06 with expirations from 2032 through 2035.